News | May 21, 2007

XTENT DES Fares Well at Six Months in Difficult-to-Treat Population

May 23, 2007 — XTENT Inc. announced positive six-month follow-up data from the CUSTOM II clinical trial, which assessed the safety and efficacy of the company's investigational Custom NX drug-eluting stent (DES) system for the treatment of long and multiple lesions in patients with coronary artery disease. Results were presented during the EuroPCR Meeting taking place this week in Barcelona.

The single-arm prospective study evaluated the use of CUSTOM NX in patients with long lesions, defined as greater than 20mm, and patients with two lesions. Of the 100 patients enrolled, 69 patients were enrolled in the long lesion arm, and 31 patients were enrolled in the two-lesion arm of the study.

Up to two customizable stent deployments of up to 60mm total length were evaluated in the study. The primary endpoint was Major Adverse Cardiac Events (MACE) at six months, with clinical follow-up at one, six and 12 months, then annually for five years. Angiographic and intravascular ultrasound (IVUS) follow-up was conducted at six months. The anticoagulation regimen was clopidogrel for a minimum of three months plus aspirin.

At six-month follow-up, the MACE rate was 9 percent. Early adverse events (in hospital) occurred in five patients, including four myocardial infarctions and one death. At six months, four additional patients (4 percent) underwent target lesion revascularization. Angiographic and IVUS results demonstrated in-stent late loss was 0.31mm; in-segment late loss was 0.22mm; binary restenosis rate was 7.5 percent; and the percentage of neointimal volume was 3.3 percent.

"These data are particularly encouraging considering CUSTOM II enrolled one of the most difficult-to-treat patient populations ever studied in a DES trial and also mirrored the complex disease profile physicians are most likely to see among patients presenting today with coronary artery disease," said Professor Eberhard Grube, MD, chief of cardiology at the Helios Heart Center in Siegburg, Germany and principal investigator of the CUSTOM II trial, who presented the data at the annual EuroPCR meeting in Barcelona. "Despite the complexity of patients treated, the Custom NX system allowed for very favorable results."

In the CUSTOM II patient population, the average vessel diameter was 2.57mm and the average lesion length was 28.7mm. Of the 100 patients enrolled in the trial, 26 percent were diabetic. The percentage of patients with ACC/AHA lesion grade B2 or C was 65.1 percent. This trial includes a high percentage of patients with complex lesions and one of the longest average lesion lengths studied of any DES clinical trial.

For more information visit www.xtentinc.com.

Related Content

Abbott Initiates XIENCE Short DAPT Clinical Trial
News | Antiplatelet and Anticoagulation Therapies| August 03, 2017
Abbott recently announced the first patient has been enrolled in a clinical study evaluating the short-term use of...
Onyx DES 2.0 mm stent meets primary endpoints in small vessels
News | June 12, 2017
June 12, 2017 – The Medtronic Resolute Onyx Drug-Eluting Stent (DES) met its primary endpoint of target lesion failur
First Pennsylvania Patient Treated in LEADERS FREE II Trial of BioFreedom Drug-Coated Stent
News | Stents Drug Eluting| May 12, 2017
PinnacleHealth CardioVascular Institute enrolled the first patient in Pennsylvania in a trial assessing the safety and...
Resolute Onyx DES, drug eluting stent, medtronic, gains FDA approval
Technology | Stents Drug Eluting| May 01, 2017
May 1, 2017 — The U.S.
Sponsored Content | Videos | Stents Drug Eluting| May 01, 2017
This video, provided by Medtronic, demonstrates the Resolute Onyx coronary stent.
Biosensors, BioFreedom drug-coated stent, LEADERS FREE II IDE trial, first patient, U.S. pivotal study
News | Stents Drug Eluting| March 03, 2017
Biosensors International Group Ltd. announced in February enrollment of the first patient in LEADERS FREE II, its new...
CeloNova Cobra Pzf stent
Technology | Stents| March 02, 2017
March 2, 2017 — The U.S. Food and Drug Administration (FDA) cleared CeloNova BioSciences Inc.
Synergy stent, abluminal polymer DES, bioresorbable polymer DES, bioresorbable polymer metallic stent

The Synergy stent is the first FDA cleared drug-eluting stent to use a bioresorbable polymer drug carrier. When the polymer dissolves after about four months, the devices become a bare metal stent. The technology is supposed to reduce the rate of late stent thrombosis due to vessel inflammation caused by durable polymers.

Feature | Stents Bioresorbable| January 17, 2017 | Dave Fornell
One of the big advancements in drug-eluting stent (DES) technology has been the development of bioresorbable polymers
OCT, intravascular imaging, stent, good stent apposition on vessel wall, TRANSFORM-OCT study

An OCT image showing good stent strut apposition against the vessel wall.

News | Stents| January 13, 2017
January 13, 2017 — Results from TRANSFORM-OCT, a prospective, randomized trial using optical coherence tomography (OC
EXCEL Trial, TCT 2016, drug-eluting stents, CABG, surgery left main heart disease, LMCAD

Gregg W. Stone, M.D., presenting the EXCEL data at TCT 2016 during a standing room only late-breaking trial session.

Feature | Stents| January 12, 2017 | Dave Fornell
The biggest news from the 2016 Transcatheter Cardiovascular Therapeutics (TCT) meeting this past fall was the results
Overlay Init